

# Contents

Preface .....	v
List of Contributors .....	vii
Abbreviations .....	xvii
<b>1 Physiology of bile formation: Hepatocellular bile salt transporters</b> .....	1
1.1 Introduction .....	1
1.2 Sodium-dependent bile salt uptake into hepatocytes .....	3
1.3 Sodium-independent bile salt uptake into hepatocytes .....	7
1.4 Bile salt export across the canalicular membrane .....	8
1.5 Bile salt salvage systems .....	12
1.6 Concluding remarks .....	12
1.7 References .....	13
<b>2 Structure and function of hepatic ABC transporters</b> .....	23
2.1 Introduction to human ABC transporters expressed in the liver .....	23
2.2 Structure and function of the bile salt export pump (ABCB11; BSEP) .....	25
2.3 Structure and function of the multidrug resistance protein 3 (ABCB4; MDR3) .....	32
2.4 Structure and function of the breast cancer resistance protein (ABCG2; BCRP) .....	37
2.5 Concluding remarks .....	40
2.6 References .....	41
<b>3 Short- and long-term regulation of hepatobiliary transport</b> .....	49
3.1 Introduction .....	49
3.2 Short-term regulation of sinusoidal transport systems .....	49
3.3 Long-term regulation of sinusoidal transport systems .....	51
3.4 Short-term regulation of canalicular secretion .....	54
3.5 Long-term regulation of canalicular transport systems .....	56
3.6 Methods of studying subcellular transporter distribution .....	58
3.7 Summary .....	59
3.8 References .....	60
<b>4 Nuclear bile acid receptor FXR and hepatobiliary transport systems</b> .....	71
4.1 Introduction .....	71
4.2 Nuclear receptors .....	71
4.3 Bile acids and the enterohepatic circulation .....	74
4.4 Bile acid homeostasis, enterohepatic circulation, and FXR .....	75
4.5 The role of FXR in the pathogenesis of biliary diseases .....	79

4.6	Concluding remarks .....	80
4.7	References.....	81
<b>5</b>	<b>Bile acid signaling in the liver and the biliary tree.....</b>	<b>85</b>
5.1	Introduction.....	85
5.2	Bile acid signaling in liver parenchymal cells (hepatocytes) .....	85
5.3	Bile acid signaling in sinusoidal endothelial cells .....	89
5.4	Bile acid signaling in Kupffer cells .....	90
5.5	Bile acid signaling in hepatic stellate cells .....	91
5.6	Bile acid signaling in the biliary tree.....	93
5.7	References.....	96
<b>6</b>	<b>Modulation of innate immunity and inflammation by bile acids and their receptors.....</b>	<b>103</b>
6.1	Introduction.....	103
6.2	Impact of FXR deletion on immunity and inflammation – lessons from FXR knockout mice .....	106
6.3	Role of TGR5 in the modulation of immune function.....	108
6.4	Effects of bile acids on immunological function independently of bile acid receptors.....	109
6.5	Obstructive jaundice and its impact on immune function .....	110
6.6	Role of bile acids and FXR in viral infections .....	111
6.7	Concluding remarks .....	111
6.8	References.....	112
<b>7</b>	<b>Bile acids as extrahepatic and interorgan signaling molecules .....</b>	<b>117</b>
7.1	Introduction.....	117
7.2	Bile acid–dependent modulation of glucose homeostasis .....	118
7.3	Impact of bile acids on energy expenditure .....	120
7.4	Bile acid receptors and immune response.....	120
7.5	Role of bile acid receptors in the cardiovascular system .....	121
7.6	Role of bile acid receptors in the kidney .....	122
7.7	Bile acid receptors in the central and peripheral nervous system .....	124
7.8	Summary and future perspectives .....	124
7.9	References.....	125
<b>8</b>	<b>Disorders of bile duct development.....</b>	<b>131</b>
8.1	Introduction.....	131
8.2	Morphogenesis of the intrahepatic bile duct epithelium: molecular players involved and their relationship with arterial morphogenesis.....	131
8.3	Ductal plate malformation (DPM): definition, clinical heterogeneity, and classification based on animal models .....	136
8.4	Cilia in cholangiocytes: a multifunctional transducing system.....	136
8.5	DPM-related cholangiopathies .....	138
8.6	Alagille’s syndrome (AGS) .....	145
8.7	References.....	146

<b>9 Mutations of the bile salt export pump (BSEP) and multidrug-resistance protein 3 (MDR3)</b>	151
9.1 Introduction	151
9.2 BSEP-related liver diseases	151
9.3 MDR3-related liver diseases	158
9.4 Treatment of BSEP- and MDR3-associated liver diseases	162
9.5 Concluding remarks	162
9.6 References	163
<b>10 MRP2 (ABCC2) and disorders of bilirubin handling in liver</b>	171
10.1 Introduction	171
10.2 The conjugate efflux pump MRP2 in the hepatocyte canalicular membrane	171
10.3 Formation of unconjugated bilirubin and its uptake into hepatocytes	173
10.4 Formation of bilirubin glucuronides and their transport into bile by MRP2	174
10.5 Uptake of bilirubin glucuronides into hepatocytes	174
10.6 MRP3, a basolateral efflux pump, contributes to conjugated hyperbilirubinemia	175
10.7 Genetic disorders and drug-induced inhibition of bilirubin uptake into hepatocytes	175
10.8 Genetic variants of the <i>MRP2 (ABCC2)</i> gene and MRP2 deficiency in Dubin-Johnson syndrome	176
10.9 Impairment of MRP2 localization in the hepatocyte canalicular membrane	177
10.10 References	177
<b>11 Hepatobiliary transport during pregnancy: Cross talk between transporters and hormones</b>	183
11.1 Introduction	183
11.2 Estrogens as cholestatic agents	183
11.3 Cholestatic activity of progesterone	185
11.4 Biochemical observations in symptom-free pregnant women	186
11.5 Genetic lessons from congenital cholestasis	186
11.6 Transporter variants and cholestasis of pregnancy	187
11.7 Nuclear receptors and cholestasis of pregnancy	189
11.8 Gallstones and pregnancy	189
11.9 Concluding remarks	190
11.10 References	190
<b>12 Hepatobiliary transport and gallstone formation</b>	195
12.1 Introduction	195
12.2 Epidemiology and risk factors of cholelithiasis	195
12.3 Hepatobiliary transporters and the pathophysiology of gallstone formation	196

12.4	Genetic variation in hepatobiliary transporter genes and gallstone susceptibility.....	199
12.5	Concluding remarks .....	202
12.6	References.....	203
<b>13</b>	<b>Molecular basis of primary biliary cirrhosis .....</b>	<b>207</b>
13.1	Introduction .....	207
13.2	Pathogenesis of PBC .....	210
13.3	Concluding remarks .....	214
13.4	References.....	215
<b>14</b>	<b>The molecular basis of primary sclerosing cholangitis .....</b>	<b>223</b>
14.1	Introduction .....	223
14.2	Immune-mediated bile duct injury .....	227
14.3	Toxic bile duct injury .....	231
14.4	Fibrosis and cirrhosis.....	232
14.5	Cancer development .....	233
14.6	Concluding remarks .....	233
14.7	References.....	235
<b>15</b>	<b>Drug-induced cholestatic liver injury .....</b>	<b>241</b>
15.1	Introduction .....	241
15.2	Diagnostic criteria of drug-induced cholestasis.....	241
15.3	Hepatocellular drug concentration .....	242
15.4	Hepatic bile salt accumulation .....	244
15.5	Susceptibility to drug-induced cholestasis .....	245
15.6	Concluding remarks .....	247
15.7	References.....	247
<b>16</b>	<b>Bile acids and receptors: Therapeutic relevance .....</b>	<b>253</b>
16.1	Introduction .....	253
16.2	Nuclear and membrane BA receptors: general concepts.....	253
16.3	Therapeutic potential of BAs .....	254
16.4	Role of BA receptors in BA homeostasis and bile production: therapeutic implications in cholestasis.....	254
16.5	Role of BA receptors for targeting hepatic inflammation and fibrosis .....	257
16.6	Role of BA receptors in the pathogenesis and treatment of gallstone disease .....	258
16.7	BA receptors in intestine: therapeutic implications for the gut-liver axis and inflammatory bowel disease.....	259
16.8	Role of BAs in lipid metabolism: therapeutic implications for atherosclerosis and nonalcoholic fatty liver disease (NAFLD) .....	260
16.9	Role of BAs in hepatic glucose metabolism and beyond .....	262
16.10	BA receptors in hepatobiliary and colorectal cancer.....	264
16.11	BA receptors beyond the liver and gastrointestinal tract.....	265

16.12 Concluding remarks ..... 265

16.13 References ..... 266

**17 Analysis of bile acids by tandem mass spectrometry..... 277**

17.1 Introduction ..... 277

17.2 Experimental procedures ..... 278

17.3 Applications ..... 281

17.4 Summary ..... 286

17.5 References..... 287

Index ..... 289